Kiniksa Pharmaceuticals International (KNSA) EBT (2017 - 2026)

Kiniksa Pharmaceuticals International has reported EBT for 10 years, with the latest figure at $32.7 million in Q1 2026.

• For the quarter ending Q1 2026, EBT rose 109.96% year-over-year to $32.7 million; the trailing twelve-month figure through Mar 2026 stood at $106.0 million (up 7675.79% YoY), and the FY2025 full-year result was $88.9 million, up 412.06% from the prior year.
• EBT for Q1 2026 stood at $32.7 million, up from $23.3 million in the prior quarter.
• The five-year high for EBT was $46.7 million in Q3 2022, with the low at -$88.3 million in Q4 2022.
• Historically, EBT has averaged -$4.8 million across 5 years, with a median of -$7.2 million in 2024.
• Annual changes were most pronounced in 2023 — EBT sank 118.19% — and 2025, when it soared 892.93%.
• Kiniksa Pharmaceuticals International's EBT stood at -$88.3 million in 2022, then rose by 18.38% to -$72.0 million in 2023, then surged by 87.08% to -$9.3 million in 2024, then jumped by 350.07% to $23.3 million in 2025, then jumped by 40.45% to $32.7 million in 2026.
• The last three EBT figures came in at $32.7 million (Q1 2026), $23.3 million (Q4 2025), and $27.2 million (Q3 2025), per Business Quant data.